News
CABA
3.820
-1.55%
-0.060
Weekly Report: what happened at CABA last week (0504-0508)?
Weekly Report · 1d ago
Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise
Simply Wall St · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (CABA), Inspire Medical Systems (INSP) and UnitedHealth (UNH)
TipRanks · 6d ago
Assessing Cabaletta Bio (CABA) Valuation After 10 Year Cellares Supply Deal And Upcoming Rese Cel Data
Simply Wall St · 6d ago
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
TipRanks · 05/05 01:35
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 05/04 17:06
Cabaletta Bio Shares Rise After $150M Underwritten Offering Prices
Dow Jones · 05/04 14:38
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Benzinga · 05/04 13:54
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
TipRanks · 05/04 12:54
Cabaletta Bio Price Target Maintained With a $30.00/Share by Cantor Fitzgerald
Dow Jones · 05/04 12:50
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target
Benzinga · 05/04 12:40
Cabaletta Bio prices $150M stock offering
Seeking Alpha · 05/04 11:03
Cabaletta Bio publishes corporate presentation on rese-cel CD19 CAR-T autoimmune disease program
PUBT · 05/04 10:57
Cabaletta Bio Announces $150 Million Equity Offering
TipRanks · 05/04 10:54
*Cabaletta Bio Announces Pricing of $150M Underwritten Offering
Dow Jones · 05/04 10:41
Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development
Benzinga · 05/04 10:38
Cabaletta Bio prices 51,725,000-share offering at $2.9, raises $150 million
PUBT · 05/04 10:36
CABALETTA BIO INC - PURCHASE PRICE FOR COMMON STOCK SET AT $2.90 PER SHARE
Reuters · 05/04 10:35
CABALETTA BIO ANNOUNCES PRICING OF $150 MILLION UNDERWRITTEN OFFERING
Reuters · 05/04 10:35
Press Release: Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Dow Jones · 05/04 10:35
More
Webull provides a variety of real-time CABA stock news. You can receive the latest news about Cabaletta Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.